DDInter609 DDInter1676
Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways. As an interleukin-4 receptor alpha antagonist, dupilumab inhibits the signaling of pro-inflammatory cytokines, called interleukins (IL), that induce inflammatory and immunological reactions in several atopic or allergic conditions, such as eczema, allergic reaction, and rhinosinusitis. Dupilumab was generated by recombinant DNA technology in Chinese Hamster Ovary cell suspension culture. Dupilumab is commonly marketed as Dupixent, which is available as a formulation for subcutaneous injection. It was first approved by the FDA in 2017. It is currently used to treat atopic dermatitis, asthma as an add-on maintenance treatment, chronic rhinosinusitis with nasal polyposis, and eosinophilic es
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Dupilumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Dupilumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alemtuzumab
Dupilumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diroximel fumarate
Dupilumab {u} may lead to a major life threatening interaction when taken with {v} Fingolimod
Dupilumab {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Dupilumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Dupilumab may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab
Dupilumab may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Dupilumab may lead to a major life threatening interaction when taken with Fingolimod
Dupilumab may lead to a major life threatening interaction when taken with Upadacitinib